Carol K Conrad1, Haley Hedlin2, Hyunsook Chin3, Don Hayes4, Peter S Heeger5, Albert Faro6, Samuel Goldfarb7, Ernestina Melicoff-Portillo8, Mohanakumar Thalachallour9, Jonah Odim10, Marc Schecter11, Gregory A Storch12, Gary A Visner13, Nikki M Williams10, Karen Kesler3, Lara Danziger-Isakov3, Stuart C Sweet11. 1. Department of PediatricsStanford University School of Medicine, Palo Alto, California, USA. 2. Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California, USA. 3. Rho Federal Systems, Durham, North Carolina, USA. 4. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 5. Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 6. Cystic Fibrosis Foundation, Bethesda, Maryland, USA. 7. Masonic Children's Hospital, University of Minnesota, Minneapolis, Minnesota, USA. 8. Texas Children's Hospital, Houston, Texas, USA. 9. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. 10. National Institutes of Health, NIAID, Bethesda, Maryland, USA. 11. University of Florida, Gainsville, Florida, USA. 12. Washington University School of Medicine, St. Louis, Missouri, USA. 13. Boston Children's Hospital, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Long-term survival after lung transplantation (LTx) is limited by chronic lung allograft dysfunction (CLAD). METHODS: We report an analysis of cytokine profiles in bronchoalveolar lavage samples collected during a prospective multicenter non-interventional trial primarily designed to determine the impact of community-acquired respiratory viral infections (CARV) in outcomes after pediatric LTx. In this analysis, we identify potential biomarkers of auto-inflammation and auto-immunity associated with survival and risk of bronchiolitis obliterans (BOS) after LTx with cytokine analysis of bronchoalveolar lavage fluid (BALF) from 61 pediatric recipients. RESULTS: Higher IL-23 (p = .048) and IL-31 (p = .035) levels were associated with the risk of BOS, and lower levels of epithelial growth factor (EGF) (p = .041) and eotaxin (EOX) (p = .017) were associated with BOS. Analysis using conditional inference trees to evaluate cytokines at each visit associated with survival identified soluble CD30 (p < .001), pro-inflammatory cytokine IL-23 (p = .02), and sTNFRI (p = .01) below cutoff levels as associated with BOS-free survival. CONCLUSIONS: Our results indicate that post-LTx survival in children may be linked to activation of alternate pathways of the immune system that affect airway remodeling in addition to activation of "classical" pathways that have been described in adult LTx recipients. These may indicate pathways to target for intervention.
BACKGROUND: Long-term survival after lung transplantation (LTx) is limited by chronic lung allograft dysfunction (CLAD). METHODS: We report an analysis of cytokine profiles in bronchoalveolar lavage samples collected during a prospective multicenter non-interventional trial primarily designed to determine the impact of community-acquired respiratory viral infections (CARV) in outcomes after pediatric LTx. In this analysis, we identify potential biomarkers of auto-inflammation and auto-immunity associated with survival and risk of bronchiolitis obliterans (BOS) after LTx with cytokine analysis of bronchoalveolar lavage fluid (BALF) from 61 pediatric recipients. RESULTS: Higher IL-23 (p = .048) and IL-31 (p = .035) levels were associated with the risk of BOS, and lower levels of epithelial growth factor (EGF) (p = .041) and eotaxin (EOX) (p = .017) were associated with BOS. Analysis using conditional inference trees to evaluate cytokines at each visit associated with survival identified soluble CD30 (p < .001), pro-inflammatory cytokine IL-23 (p = .02), and sTNFRI (p = .01) below cutoff levels as associated with BOS-free survival. CONCLUSIONS: Our results indicate that post-LTx survival in children may be linked to activation of alternate pathways of the immune system that affect airway remodeling in addition to activation of "classical" pathways that have been described in adult LTx recipients. These may indicate pathways to target for intervention.
Authors: Joshua M Diamond; Selim Arcasoy; Cassie C Kennedy; Michael Eberlein; Jonathan P Singer; Glenda M Patterson; Jeffrey D Edelman; Gundeep Dhillon; Tahuanty Pena; Steven M Kawut; James C Lee; Reda Girgis; John Dark; Gabriel Thabut Journal: J Heart Lung Transplant Date: 2017-07-26 Impact factor: 10.247
Authors: A Jaramillo; M A Smith; D Phelan; S Sundaresan; E P Trulock; J P Lynch; J D Cooper; G A Patterson; T Mohanakumar Journal: Transplantation Date: 1999-04-27 Impact factor: 4.939
Authors: Matthew R Morrell; Joseph M Pilewski; Cynthia J Gries; Matthew R Pipeling; Maria M Crespo; Christopher R Ensor; Samuel A Yousem; Jonathan D'Cunha; Norihisa Shigemura; Christian A Bermudez; John F McDyer; Adriana Zeevi Journal: J Heart Lung Transplant Date: 2014-08-23 Impact factor: 10.247
Authors: Don Hayes; Wida S Cherikh; Daniel C Chambers; Michael O Harhay; Kiran K Khush; Rebecca R Lehman; Bruno Meiser; Joseph W Rossano; Eileen Hsich; Luciano Potena; Aparna Sadavarte; Tajinder P Singh; Andreas Zuckermann; Josef Stehlik Journal: J Heart Lung Transplant Date: 2019-08-08 Impact factor: 10.247
Authors: Jens Gottlieb; Thomas F Schulz; Tobias Welte; Thomas Fuehner; Martin Dierich; Andre R Simon; Ilka Engelmann Journal: Transplantation Date: 2009-05-27 Impact factor: 4.939